# POTENTIAL FOR VIRUS IMMUNOTHERAPY BY T CELL BLASTS

> **NIH NIH R01** · UNIVERSITY OF COLORADO DENVER · 1987 · $113,676

## Abstract

Adoptive transfer of cell mediated immunity is a widely acknowledged long
term goal (NIAID).  Our studies focus on aspects relevant in the context of
severe or progressive herpesvirus infections in patients with secondary
immunodeficiency:  how can T cells of defined specificity be cultured in
vitro, what are the requirements of different T and NK cell subsets for
help and how can their function be characterized?  VZV is selected as the
model herpesvirus because it is clinically important in immunosuppressed
subjects.  The approach will be:  1. stimulate blood mononuclear cells
(MNC) from healthy donors with VZV presented as extracted antigen on
autologous monocytes, or as VZV infected fibroblasts or lymphoblasts, HLA
matched with the responder T cells for class I or class II major
histocompatibility (MHC) antigens.  Responding T cells will be phenotyped
by monoclonal antibodies to define optimal conditions for responses by
individual subsets.  2. Deplete MNC of monocytes or single T subsets to
determine whether different responder subsets have different accessory or
helper cell requirements.  3. Cells from stimulated cultures will be tested
for MHC restricted cytotoxicity using the fibroblast and lymphoblast
targets as these differ in their VZV as well as MHC antigen expression.  4.
T cells from cultures stimulated under conditions defined in 1 will be
cloned and tested for (a) cytotoxicity (b) help for in vitro antibody
production and (c) IL 2 production.  5. The possible recognition of
different VZV antigens by MHC class I or II restricted T cells will be
tested by proliferation or cytotoxicity inhibition by VZV glycoproteins
isolated by affinity chromatography.  6. The development of VZV immunity in
healthy subjects receiving VZV immunization will be followed (a) for
comparison with immunity to wild type VZV and (b) to provide a reference
group for responses in elderly subjects before and after booster
immunization.  Or studies would provide a detailed view of immunity to a
clinically important virus, VZV, and the means for culturing functionally
restricted VZV specific T cells.

## Key facts

- **NIH application ID:** 3128328
- **Project number:** 5R01AI018941-05
- **Recipient organization:** UNIVERSITY OF COLORADO DENVER
- **SAM.gov UEI:** MW8JHK6ZYEX8
- **Principal Investigator:** Anthony R. Hayward
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $113,676
- **Award type:** 5
- **Project period:** 1983-07-01 → 1989-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3128328

## Citation

> US National Institutes of Health, RePORTER application 3128328, POTENTIAL FOR VIRUS IMMUNOTHERAPY BY T CELL BLASTS (5R01AI018941-05). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3128328. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*